0001193125-26-048957
SEC filingCRISPR Therapeutics AG (CRSP) reported FY 2025 total revenue of $3.5M, primarily from collaboration activities, amid heavy R&D investment. Operating expenses reached $668.1M, driven by $284.8M in research and development, $96.3M in acquired in-process R&D, $73.5M in general and administrative, and $213.5M net collaboration expense, resulting in a $664.6M operating loss. Other income of $86.6M partially offset costs, leading to a net loss of $581.6M or -$6 per share (basic and diluted), based on 89.9M weighted-average shares. Balance sheet remains robust with $2.27B total assets, including $347.6M cash equivalents and $1.63B marketable securities; total current assets $1.99B against $149.1M current liabilities, yielding $1.92B shareholders' equity. Cash flow showed -$345.0M used in operations, -$31.8M in investing, offset by $426.0M from financing (primarily $398.1M common shares issuance), increasing cash by $49.3M to $224.1M (including restricted). No prior year figures disclosed; strong liquidity supports ongoing gene-editing pipeline advancement despite losses typical for clinical-stage biotech.
CRISPR Therapeutics AG reported FY 2025 results with total revenue of $3.5M. Operating expenses totaled $668.1M, comprising research and development at $284.8M, acquired in-process research and development at $96.3M, general and administrative at $73.5M, and collaboration expense net at $213.5M. This drove a loss from operations of -$664.6M. Other income net of $86.6M reduced the net loss before taxes to -$578.0M; after $3.6M provision for income taxes, net loss was -$581.6M. Comprehensive loss reached -$578.6M after foreign currency translation adjustment of $95K and unrealized gain on marketable securities of $2.9M. Net loss per common share was -$6 basic and diluted, on 89.9M weighted-average shares. No prior period comparisons provided in the filing. Total assets stood at $2.27B with shareholders' equity of $1.92B.
Total revenue was $3.5M for FY 2025. No breakdown by product, service, collaboration revenue member, or grant revenue member was disclosed. No geographic mix or growth drivers detailed in the provided data. Revenue remains minimal, consistent with clinical-stage biotech focused on pipeline development rather than commercialization.
No gross profit or gross margin disclosed due to negligible revenue relative to costs. Operating loss of -$664.6M on $3.5M revenue implies deeply negative operating margin, driven by high R&D and collaboration expenses. Net loss margin effectively -16,617% reflecting $581.6M loss on $3.5M revenue. Cost structure dominated by operating expenses at $668.1M, with significant non-cash acquired in-process R&D at $96.3M. No prior year trends available.
Net cash used in operating activities was -$345.0M, adjusted from -$581.6M net loss by $19.5M depreciation, $72.5M stock-based compensation, $96.3M acquired IPRD, and working capital changes including -$25.0M accounts receivable and +$44.9M payables/accrued. Investing used -$31.8M net, with $1.01B marketable securities purchases offset by maturities, plus IPRD purchase $25.0M. Financing provided $426.0M, led by $398.1M common shares issuance net. Cash increased $49.3M; end cash, equivalents, restricted $224.1M (cash equivalents $347.6M, restricted $7.6M noted separately). Balance sheet: $1.99B current assets vs. $149.1M current liabilities; total liabilities $343.4M, no debt specified.
No management guidance, strategic priorities, or risk factors explicitly disclosed in the provided filing excerpt. Commitments and contingencies noted in Note 9, but details unavailable. Focus implied on sustaining R&D via equity financing and liquidity.